

Biomea Fusion Information
Summary
Biomea Fusion is a public company that has been in the industry for 8 years. The company currently specializes in the Biotechnology, Health Care Technology areas. The position of the Co-Founder & CEO is occupied by Thomas Butler. Its headquarters is located at Redwood City, California, USA. The number of employees ranges from 1 to 25. The Biomea Fusion annual revenue is estimated at < 1M. Total funding of the company - $209M. To connect with Biomea Fusion employee register on SignalHire.
Industries
Biotechnology
Headquarters Location
Employees Size
100-200 employees
Specialties
Biotech, Oncology, Patient Friendly Therapies , Targeted Medicine , Cancer Treatment, Acute Myeloid Leukemia, MLL Fusion, Diabetes Mellitus, Liquid Tumors, Solid Tumors, Innovative Medicine , Novel Mechanism of Action, Menin, Irreversible Inhibitors
DMA Code
San Francisco Bay Area
Founded
2017
Operating Status
Independent Company
Competitors
Founded | Type | Employees | Revenue | Funding | |
---|---|---|---|---|---|
2015 | Public Company | 1 - 25 | 1.2M | $335.4M | |
2008 | Privately Held | 25 - 100 | 2.2M | $160.5M | |
1999 | Public Company | 250 - 500 | 73.9M | $271.9M | |
2009 | Public Company | 25 - 100 | < 1M | $204.2M | |
1993 | Public Company | 1.0K - 5.0K | 50.2M | $526.4M | |
2009 | Privately Held | 25 - 100 | 5M | $230M | |
2020 | Privately Held | 1 - 25 | < 1M | $258M | |
2018 | Privately Held | 25 - 100 | 2.5M | $113.8M | |
2013 | Public Company | 1.0K - 5.0K | 106M | $1.5B | |
1996 | Public Company | 1 - 25 | < 1M | $113.7M | |
2009 | Privately Held | 25 - 100 | 5.6M | $197.7M | |
2016 | Privately Held | 25 - 100 | 14.2M | $174M | |
2014 | Public Company | 25 - 100 | 3.3M | $291.3M | |
2005 | Public Company | 25 - 100 | 1.5M | $193.9M | |
1991 | Public Company | 1 - 25 | 4.4M | $362.1M | |
1979 | Public Company | 250 - 500 | 6.5M | $296.4M | |
2018 | Privately Held | 64 | < 1M | $260M | |
2020 | - | 1 - 25 | < 1M | $50M | |
1994 | Public Company | 200-500 | - | $- | |
2013 | - | 10-50 | - | $- | |
2012 | - | 100-200 | - | $- | |
2011 | - | 100-200 | - | $- | |
2019 | - | 10-50 | - | $- | |
2016 | - | 10-50 | - | $- |